ストックスクリーナーアプリを入手
11.71
0.67%
-0.15
前日終値:
$11.86
開ける：
$11.91
24時間の取引高:
317.98K
Relative Volume:
0.20
時価総額：
$1.31B
収益：
$577.74M
当期純損益:
$-149.78M
株価収益率:
-8.3643
EPS:
-1.4
ネットキャッシュフロー:
$-78.21M
1週間 パフォーマンス:
+1.46%
1か月 パフォーマンス:
-12.68%
6か月 パフォーマンス:
-36.56%
1年 パフォーマンス:
-33.89%
1日の値動き範囲:
$11.70
$11.96
1週間の範囲:
$10.70
$12.01
52週間の値動き範囲:
$10.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
NVCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
11.76 | 1.26B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
128.37 | 218.91B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
103.99 | 149.59B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
370.08 | 135.77B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
95.98 | 118.85B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
85.53 | 48.79B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Novocure (NASDAQ: NVCR) at Jefferies Healthcare, 2:00 p.m. GMT; webcast, 14-day replay - Stock Titan
Using flow based indicators on NovoCure LimitedJuly 2025 Rallies & Real-Time Volume Analysis - newser.com
What sentiment indicators say about NovoCure Limited stock2025 Sector Review & Proven Capital Preservation Methods - newser.com
Why NovoCure Limited (038) stock could rally stronglyEarnings Recap Report & Daily Profit Maximizing Tips - newser.com
NovoCure (NVCR): Assessing Valuation Following Q3 Sales Growth and Rising Net Losses - simplywall.st
Novocure stock hits 52-week low at 10.82 USD By Investing.com - Investing.com Canada
Novocure stock hits 52-week low at 10.82 USD - Investing.com
Can NovoCure Limited hit a new high this monthM&A Rumor & Fast Entry High Yield Stock Tips - newser.com
Can momentum traders help lift NovoCure LimitedMarket Trend Report & Reliable Intraday Trade Plans - newser.com
Will NovoCure Limited stock attract more institutional investors2025 Technical Patterns & Free Fast Entry Momentum Trade Alerts - newser.com
Oversold Conditions For NovoCure (NVCR) - Nasdaq
[Form 4] NovoCure Ltd Insider Trading Activity - Stock Titan
Novocure Ltd. Reports Q3 2025 Financial Results - MSN
Can NovoCure Limited stock deliver sustainable ROETrade Volume Summary & Fast Exit Strategy with Risk Control - newser.com
NovoCure (NVCR) Is Down 5.7% After Q3 Revenue Growth and Expanded International Coverage — Has the Growth Story Changed? - simplywall.st
Measuring NovoCure Limited’s beta against major indicesPrice Action & Reliable Volume Spike Trade Alerts - newser.com
HC Wainwright Increases Earnings Estimates for NovoCure - MarketBeat
Chart overlay techniques for tracking NovoCure LimitedQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - newser.com
How to recover losses in NovoCure Limited stockQuarterly Market Summary & Stepwise Entry/Exit Trade Alerts - newser.com
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Breakouts & Weekly Setup with High ROI Potential - newser.com
Is NovoCure Limited stock attractive for hedge fundsGDP Growth & Pattern Based Trade Signal System - newser.com
Is NovoCure Limited stock oversold or undervaluedGap Up & Weekly Momentum Stock Picks - newser.com
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Q3 2025 Earnings Call Transcript - Insider Monkey
How interest rate cuts could boost NovoCure Limited stockJuly 2025 Opening Moves & Verified Chart Pattern Signals - newser.com
What does recent volatility data suggest for NovoCure LimitedJuly 2025 Reactions & Consistent Profit Trade Alerts - newser.com
NovoCure’s Mixed Q3: Growth Amid Challenges - TipRanks
NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential - simplywall.st
Novocure’s Revenue Beats Forecasts As Cancer Pipeline Expands - Finimize
NovoCure (NASDAQ:NVCR) Announces Quarterly Earnings Results - MarketBeat
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
NovoCure: Q3 Earnings Snapshot - Stamford Advocate
Novocure Ltd earnings beat by $0.09, revenue topped estimates - Investing.com UK
Emerald Mutual Fund Advisers Trust Reduces Position in NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR) Valuation Discount Contrasts With Persistent Losses and Unprofitability Challenges - Yahoo Finance
NovoCure Expands Global Reach Within Nasdaq Today Trends - Kalkine Media
Cash per share of NovoCure Ltd. – BER:038 - TradingView
Order flow analysis tools used on NovoCure Limited2025 Top Decliners & AI Driven Price Predictions - newser.com
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
NovoCure’s TIGER France Study: A Potential Game-Changer for Glioblastoma Treatment - MSN
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
HC Wainwright & Co. Raises PT for NVCR, Maintains Buy Rating | N - GuruFocus
Assessing NovoCure (NVCR) Valuation as Investors Revisit Recovery Potential - simplywall.st
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges - Yahoo Finance
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Novocure (NVCR) Exceeds Q3 Revenue Expectations with Strong Grow - GuruFocus
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimat - GuruFocus
Emerald Advisers LLC Lowers Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure’s LUNAR-4 Study: A New Horizon in Lung Cancer Treatment - MSN
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
Novocure Ltd (NVCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
0.55%
大文字化:
|
ボリューム (24 時間):